Recent progress in Cetuximab-based treatment for Triple-NegativeBreast Cancer
DOI:
https://doi.org/10.61173/zn9r0r21Keywords:
TNBC treatment, YM-1, BAG3Abstract
This study verifies the preclinical therapeutic effect of YM-1 silencing BAG3 combined with cetuximab targeted at
epidermal growth factor receptor (EGFR) on Triple-Negative Breast Cancer (TNBC ) cell lines both in vitro and in
vivo. TNBC is defined as a unique subtype of breast cancer that leads to an increase in patients with interval cancers
which can be detected annually. In actual research, targeted molecular therapies are involved in the field because of the
immunological heterogeneity of TNBC. YM-1 has a potentially better inhibition target for EGFR instead of BAG3. By
reviewing some existing preclinical research and targeted treatment for TNBC, this study is to propose a novel treatment
target for TNBC based on cetuximab treatment.
References
[1] Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H. J., & Panel members (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology : official journal of the European Society for Medical Oncology, 24(9), 2206–2223.
[2] Chang-Qing, Y., Jie, L., Shi-Qi, Z., Kun, Z., Zi-Qian, G., Ran, X., Hui-Meng, L., Ren-Bin, Z., Gang, Z., Da-Chuan, Y., & Chen-Yan, Z. (2020). Recent treatment progress of triple negative breast cancer. Progress in biophysics and molecular biology, 151, 40–53.
[3] Newman, L. A., Reis-Filho, J. S., Morrow, M., Carey, L. A., & King, T. A. (2015). The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Annals of surgical oncology, 22(3), 874–882.
[4] Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation, 121(7), 2750–2767.
[5] Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., Cristofanilli, M., Hortobagyi, G. N., & Pusztai, L. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(8), 1275–1281.
[6] Javle, M., & Curtin, N. J. (2011). The role of PARP in DNA repair and its therapeutic exploitation. British journal of cancer, 105(8), 1114–1122.
[7] Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., Akslen, L. A., Ragaz, J., Gown, A. M., Gilks, C. B., van de Rijn, M., & Perou, C. M. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 10(16), 5367– 5374.
[8] Takayama, S., & Reed, J. C. (2001). Molecular chaperone targeting and regulation by BAG family proteins. Nature cell biology, 3(10), E237–E241.
[9] Colvin, T. A., Gabai, V. L., Gong, J., Calderwood, S. K., Li, H., Gummuluru, S., Matchuk, O. N., Smirnova, S. G., Orlova, Dean&Francis N. V., Zamulaeva, I. A., Garcia-Marcos, M., Li, X., Young, Z. T., Rauch, J. N., Gestwicki, J. E., Takayama, S., & Sherman, M. Y. (2014). Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer research, 74(17), 4731–4740.
[10] Wang, A. M., Miyata, Y., Klinedinst, S., Peng, H. M., Chua, J. P., Komiyama, T., Li, X., Morishima, Y., Merry, D. E., Pratt, W. B., Osawa, Y., Collins, C. A., Gestwicki, J. E., & Lieberman, A. P. (2013). Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nature chemical biology, 9(2), 112–118.
[11] Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation, 121(7), 2750–2767.
[12] Robinson, D. R., Wu, Y. M., & Lin, S. F. (2000). The protein tyrosine kinase family of the human genome. Oncogene, 19(49), 5548–5557.
[13] Schlessinger J. (2000). Cell signaling by receptor tyrosine kinases. Cell, 103(2), 211–225.
[14] Wieduwilt, M. J., & Moasser, M. M. (2008). The epidermal growth factor receptor family: biology driving targeted therapeutics. Cellular and molecular life sciences : CMLS, 65(10), 1566–1584.
[15] Costa, R., Shah, A. N., Santa-Maria, C. A., Cruz, M. R., Mahalingam, D., Carneiro, B. A., Chae, Y. K., Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017). Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer treatment reviews, 53, 111–119.
[16] Barton-Burke, M., Ciccolini, K., Mekas, M., & Burke, S. (2017). Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care. The Nursing clinics of North America, 52(1), 83–113.
[17] Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., Liu, M., Das, R., Chen, Y., Tam, A., Wang, H., Liang, J., Gurski, J. M., Kerr, D. A., Rosell, R., Teixidó, C., … Baselga, J. (2015). AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer cell, 27(4), 533–546.
[18] Iancu, G., Serban, D., Badiu, C. D., Tanasescu, C., Tudosie, M. S., Tudor, C., Costea, D. O., Zgura, A., Iancu, R., & Vasile, D. (2022). Tyrosine kinase inhibitors in breast cancer (Review). Experimental and therapeutic medicine, 23(2), 114.
[19] Chen, H., Lu, W., Zhang, Y., Zhu, X., Zhou, J., & Chen, Y. (2019). A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triplenegative breast cancer. Cancer medicine, 8(1), 383–399.
[20] Tobin, N. P., Harrell, J. C., Lövrot, J., Egyhazi Brage, S., Frostvik Stolt, M., Carlsson, L., Einbeigi, Z., Linderholm, B., Loman, N., Malmberg, M., Walz, T., Fernö, M., Perou, C. M., Bergh, J., Hatschek, T., Lindström, L. S., & TEX Trialists Group (2015). Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Annals of oncology : official journal of the European Society for Medical Oncology, 26(1), 81–88.
[21] Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009). Targeting the mTOR signaling network for cancer therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(13), 2278–2287.
[22] Singh, J., Novik, Y., Stein, S., Volm, M., Meyers, M., Smith, J., Omene, C., Speyer, J., Schneider, R., Jhaveri, K., Formenti, S., Kyriakou, V., Joseph, B., Goldberg, J. D., Li, X., Adams, S., & Tiersten, A. (2014). Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast cancer research : BCR, 16(2), R32.
[23] Nagayama, A., Vidula, N., Ellisen, L., & Bardia, A. (2020). Novel antibody-drug conjugates for triple negative breast cancer. Therapeutic advances in medical oncology, 12, 1758835920915980.
[24] Lin, C. W., Zheng, T., Grande, G., Nanna, A. R., Rader, C., & Lerner, R. A. (2021). A new immunochemical strategy for triple-negative breast cancer therapy. Scientific reports, 11(1), 14875.
[25] Goldenberg, D. M., & Sharkey, R. M. (2020). Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert opinion on biological therapy, 20(8), 871–885.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
